Love Story: Lipid Education for Women’s Heart Health

ReachMD Healthcare Image
Media formats available:
Details
Presenters
Comments
  • Overview

    Cardiovascular disease (CVD) is the leading cause of death in women. Despite similar guidelines for treatment, studies show that women have worse control of dyslipidemia and have a lower likelihood of attaining LDL-C goals than men, even after therapy adjustment. This may stem from multiple contributing factors, including underestimation of CVD risk in women, decreased prescription and utilization of lipid-lowering therapies, decreased medication adherence, and a higher risk of statin intolerance. The addition of nonstatin lipid-lowering therapy to statins to achieve intensive LDL-C lowering is recommended for patients at very high risk of atherosclerotic cardiovascular disease (ASCVD) events. Tune in to review the impact of risk factors for coronary artery disease progression that are unique to women, current treatment guidelines for the management of LDL-C, and the role of nonstatin therapies in the management of high-risk ASCVD. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Pam Taub, MD, FACC
    Founder and Director of Step Family Cardiac Rehabilitation and Wellness Center
    Director of Preventive Cardiology
    Professor of Medicine
    UC San Diego Health System
    San Diego, CA 

    Dr. Taub has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Amgen, Bayer, Boehringer Ingelheim, Edwards, Esperion, Jazz, Lilly, Medtronic, Novartis, Novo Nordisk, Sanofi
    Research: Dysautonomia International, Hillblom Network, NIH R01 DK118278

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Wilma Guerra has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Demonstrate collective understanding of gender differences and challenges in optimizing LDL-C management for women, with a particular focus on practical considerations​
    • Analyze the changing landscape of LDL-C management in women by integrating the latest research findings and therapeutic insights
  • Target Audience

    This activity has been designed to meet the educational needs of cardiologists and primary care physicians as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in LDL-C management.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .5 contact hours/0.05 CEUs of pharmacy contact hours. 

    The Universal Activity Number for this program is JA0006235-0000-24-146-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .5 AAPA Category 1 CME credit(s). Approval is valid until November 27, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity 

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Esperion Therapeutics, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Omia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Register

We're glad to see you're enjoying Omnia Education…
but how about a more personalized experience?

Register for free